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Correlations between angiogenic factors and
capillaroscopic patterns in systemic sclerosis
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Camille Frances4, Gilles Chiocchia2, Maurizio Cutolo5 and Yannick Allanore1,2*
Abstract
Introduction: We sought to assess whether nailfold videocapillaroscopy (NVC) patterns are associated with levels
of angiogenic factors in systemic sclerosis (SSc).
Methods: Circulating endothelial progenitor cells (EPCs) and circulating endothelial cells (CECs) were measured in
the peripheral blood of 60 consecutive SSc patients. Serum levels of eight endothelial markers were measured first
in these 60 patients, and then in an independent replication cohort of 43 SSc patients in case of association with
NVC patterns. NVC patterns were determined by four independent investigators blinded to vascular markers.
Results: Patients with the late-NVC pattern exhibited lower EPC levels (P < 0.0001) and higher VEGF levels (P =
0.03). Higher VEGF levels were confirmed to be associated with the late-NVC pattern in the replication cohort (P =
0.01). By multivariate analysis focused on biomarkers, lower EPC (P = 0.03) and higher VEGF levels (P = 0.001) were
independently associated with the late-NVC pattern. In an alternate multivariate model including these two factors
and SSc-related disease characteristics, lower EPC counts (P = 0.005), higher VEGF levels (P = 0.01), a history of
digital ulcers (P = 0.04), and a modified Rodnan skin score > 14 (P < 0.0001) were independently associated with
the late-NVC pattern.
Conclusion: Our data revealed decreased EPC counts and increased VEGF levels in patients with the late-NVC
pattern. Further studies are now needed to determine the role of VEGF and EPCs in endothelial injury and repair in
SSc.
Introduction
Systemic sclerosis (SSc) is a severe connective tissue dis-
ease characterized by vascular, immune, and fibrotic
changes in the skin and some internal organs [1]. Early
and diffuse microvascular alterations are key features of
SSc, with outcome depending on the extent and severity
of vascular lesions. The earliest clinical symptoms of
SSc relate to disturbances in the peripheral vascular sys-
tem. Moreover, work with animal models showed that
endothelial cell apoptosis could be a primary event in
the pathogenesis of SSc [2-6]. Endothelial cell injury
results in disorganization of endothelial layer favoring
early impaired capillary architecture and loss of capil-
laries [7]. These features can be detected on nailfold
videocapillaroscopy (NVC), which shows a variety of
morphologic changes including enlarged capillaries,
bushy capillary formations, microhemorrhages, and a
variable loss of capillaries with or without avascular
areas [8,9] from the very early stages. In accordance,
NVC is used as a marker in early and even preclinical
stages of SSc [10]. This decreased capillary density,
insufficiently compensated by endothelial repair pro-
cesses, which relate to angiogenesis and vasculogenesis,
results in blood flow being insufficient and reduction of
oxygen supply that leads to tissue hypoxia. These phe-
nomena are often accompanied by abnormal levels of
angiogenic/angiostatic factors and markers of endothe-
lial cell injury, as well as disturbed vasculogenesis with
abnormal numbers of circulating endothelial progenitor
cells (EPCs) [11-17]. In addition, several vascular mar-
kers, including circulating EPCs, placenta growth factor
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(PlGF) and soluble vascular cell-adhesion molecule
(sVCAM) have been recently shown to predict the
occurrence of ischemic digital ulcers and cardiovascular
events, complications that directly relate to microvascu-
lar complications [18].
Thus, we hypothesized that microvascular abnormal-
ities with disturbed capillary architecture objectified on
NVC could be related to an impairment of selective fac-
tors reflecting disturbances of angiogenesis, endothelium
damage, and vasculogenesis. To test this hypothesis, we
assessed whether NVC changes were associated with
peripheral blood or serum levels of endothelial factors in
SSc.
Materials and methods
Patient sets
Two different cohorts were used in this study. All patients
gave informed consent for all procedures, which were
carried out with local ethics committee approval (Comité
de Consultation pour la Protection des Personnes se
prêtant à la Recherche Biomédicale (CCPPRB) Paris-
Cochin).
Discovery cohort
The first patient set consisted on consecutive patients with
SSc referred to the Rheumatology A Department over a 6-
month period for systematic follow-up. Eligible patients
were those who had been on a stable treatment regimen
for at least 3 months, including vasodilators (calcium
channel blockers, angiotensin-converting enzyme inhibi-
tors, endothelin-receptor antagonists, PDE5 inhibitors)
and immunosuppressive drugs (methotrexate, azathiopr-
ine, and prednisone dosage ≤ 10 mg/day). No patient was
treated with cyclophosphamide or prostacyclins at the
time of this study.
Clinical assessments
We systematically collected the following data: age, dis-
ease duration (date of the first non-Raynaud symptom),
duration of Raynaud phenomenon, cutaneous subset
according to the criteria reported by LeRoy et al. [19],
skin involvement according to the modified Rodnan skin
score (mRSS) [20], digital ulceration (past or current),
and treatment received.
Routine laboratory assessments
Routine laboratory studies obtained on the morning of
hospital admission included complete blood cell count,
Westergren erythrocyte sedimentation rate (ESR), C-reac-
tive protein (CRP) level, serum creatinine concentration,
levels of proteinuria and von Willebrand factor antigen
(ELISA, VIDAS von Willebrand; BioMérieux, Marcy
l’Etoile, France), and tests for anticentromere (immuno-
fluorescence on Hep2 cells) and antitopoisomerase-I anti-
bodies (counter immunoelectrophoresis).
Pulmonary and cardiac assessments
Echocardiography was performed by a senior cardiolo-
gist according to the American Society of Echocardio-
graphy recommendations. In particular, left ventricular
ejection fraction (LVEF) was determined by using the
Simpson method, and systolic PAP (sPAP) was based on
the tricuspid and/or pulmonary regurgitation, adding 10
mm Hg for auricular pressure. Pulmonary hypertension
was suspected at baseline or during follow-up based on
(a) an estimated echocardiographic systolic pulmonary
arterial pressure (sPAP) > 40 mm Hg, Or (b) a DLCO <
50% predicted in absence of pulmonary fibrosis; or (c)
unexplained dyspnea, as previously published [21,22]
and had to be confirmed by RHC as a resting mean pul-
monary artery pressure ≥ 25 mm Hg together with a
pulmonary capillary wedge pressure of ≤ 15 mm Hg
(precapillary PH).
Pulmonary involvement was assessed with chest
radiograph, computed tomography, and measurement
of forced vital capacity (FVC) and the diffusing capa-
city for carbon monoxide/alveolar volume (DLCO/AV)
ratio.
Replication cohort
This second patient set consisted on patients with SSc
recruited during a patient meeting (business meeting of
the Association des Sclérodermiques de France, Stras-
bourg, 27 April, 2012). Age, disease duration, and cuta-
neous subset according to the criteria reported by LeRoy
et al. [19] were collected for all the patients, together with
the main clinical complications and ongoing medications.
Nailfold videocapillaroscopy
NVC was performed for all patients of the two cohorts.
Patients were asked not to smoke and take caffeinated
drinks for at least 4 hours before NVC, and to remain
at least 15 minutes at 22°C to 23°C before NVC.
Collection and blinding of the NVC images
The nailfolds of the second, third, fourth, and fifth fingers
were examined bilaterally in each patient by two inde-
pendent investigators blinded for the serum status of SSc
patients (discovery cohort: JA, replication cohort: JA and
PS), by using an optical probe videocapillaroscope
equipped with a ×200 magnification contact lens and
connected to image-analysis software (Videocaps, DS
MediGroup, Milan, Italy). Four consecutive fields extend-
ing over 1 mm, in the middle of the nailfold, were studied
per finger [23,24]. The images were made anonymous
before being assessed by four independent investigators
(VS, AS, CP, MC), blinded for the clinical and serum sta-
tus of SSc patients.
Qualitative assessment of NVC images
The following NVC definitions were used for the quali-
tative assessment of the NVC patterns.
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The early NVC scleroderma pattern: the combination
of few enlarged/giant capillaries, few capillary microhe-
morrhages, a relatively well-preserved capillary distri-
bution, and no evident loss of capillaries.
The active NVC scleroderma pattern: frequent giant
capillaries, frequent capillary microhemorrhages, moder-
ate loss of capillaries, mild disorganization of the capil-
lary architecture, and absent or mild ramified capillaries.
The late-NVC scleroderma pattern: irregular enlarge-
ment of the capillaries, few or absent giant capillaries
and microhemorrhages, severe loss of capillaries with
large avascular areas, disorganization of the normal
capillary array, and ramified/bushy capillaries (7). The
Additional File 3 shows representative pictures of these
three NVC patterns.
EPC and CEC cell sorting and flow-cytometry quantification
EPC and CEC quantification were performed only in the
discovery cohort. Quantification of EPCs and CECs was
precluded in the replication cohort because this proce-
dure required fresh blood samples, and the patient meet-
ing was organized in another city than the one where our
laboratory is located. As used in previous reports, 20-ml
samples of heparinized venous blood were taken at rest
from the forearm, in the morning, at the same time as
samples collected from hospitalized patients for routine
analysis [15]. Samples were immediately transported to
the laboratory for testing. We used a method previously
described and validated to enrich mononuclear cells and
quantify EPCs and CECs [15,18,25]. Negative lineage
(Lin-) mononuclear cells were obtained by enrichment
from 20-ml peripheral blood mononuclear cells by using
1,000 ml of a human progenitor cell enrichment cocktail
(RosetteSep; StemCell Technologies, Vancouver, BC,
Canada). The enriched mononuclear cells were collected
by Ficoll density gradient centrifugation (Pancoll;
Dutcher, Brumath, France), and then washed and prein-
cubated for 15 minutes with 100 ml of an FcR blocking
reagent (Miltenyi Biotec, Paris, France) to inhibit nonspe-
cific binding or specific binding via Fc receptors. These
cells were then subjected to triple labeling for EPC or
CEC detection, according to recent recommendations
and previous publications [15]. For EPC detection, 10 ml
of enriched mononuclear cells was labeled with 5 ml of
each anti-CD133-phycoerythrin (PE, Miltenyi Biotec) and
anti-CD34-fluorescein isothiocyanate (FITC; BD
Bioscience, Le Pont de Claix, France) antibodies, and 20
ml of anti-VEGFR-2 (KDR)-allophycocyanin (APC; R&D
Systems, Minneapolis, MN, USA) antibodies. For CEC
detection, 10 ml of enriched mononuclear cells was
labeled with 5 ml each of anti-CD133-PE and anti-
CD105-FITC (AbD Serotec, Colmar, France) and 20 ml
of anti-VEGFR-2-APC. Five milliliters of 7AAD (BD
Bioscience) were used for real-time viability staining to
identify dead cells 20 minutes before flow cytometry.
Control cells were also prepared by incubation with
fluorescence-labeled isotype-matched monoclonal anti-
bodies (Beckman Coulter, Villepinte, France). The labeled
cells were analyzed by using a fluorescence-activated cell
sorter (FACS; four-color flow cytometry with a FACS
Calibur flow cytometer (BD Bioscience). A large number
of events (500,000) was considered for every sample. The
same detector sensitivity, compensation setting, and scat-
ter-gate set were used to analyze all samples. Viable cells
were identified by gating on forward/side scatters and as
the 7AAD-population. The expression of CD133 and
VEGFR-2 by gated viable CD34+ cells was assessed. The
EPC and CEC populations were identified as Lin-/
7AAD-/CD133+/CD34+/VEGFR-2+, and Lin-/7AAD-/
CD133-/CD105+/VEGFR-2+ cells, respectively. Data were
analyzed with FlowJo software (Version 7.6.5). Results
were expressed as the number of EPCs per million Lin-
mononuclear cells.
Serum levels of endothelial markers
Serum was isolated from the peripheral blood of all
patients included in the discovery and replication
cohorts. In the replication cohort, sera was also taken at
rest from the forearm, in the morning, and stored locally
before shipment to our laboratory, in the days after the
patient meeting. Serum levels of eight endothelial factors
that have been shown to be implicated in SSc (VEGF,
placenta growth factor (PlGF), sVCAM, angiopoietin-2,
endoglin, endostatin, endothelin-1 and Tie-2) were mea-
sured by using the quantitative sandwich enzyme-linked
immunosorbent assay (ELISA) technique (Quantikine
kits; R&D systems) [11-14,17,18,26-28]. No patient in our
cohort had regular alcohol consumption, which has been
reported to have an important influence on serum levels
of VEGF. Concentrations were calculated by using a stan-
dard curve generated with specific standards provided by
the manufacturer. The analytic range, and intraassay and
interassay coefficients of variation are detailed for each
marker in Additional File 1. Serum levels of these eight
endothelial markers were first assessed in the discovery
cohort. Only serum levels of endothelial markers that
were found associated with NVC patterns in the discov-
ery cohort were measured in the replication cohort.
Statistical analysis
All data are presented as median (range) for continuous
variables and numbers and percentages for categoric vari-
ables, unless stated otherwise. The c2 test was used to
compare categoric variables. In that case, patients with
early and active NVC patterns were merged and further
compared with patients with the late-NVC pattern. Com-
parisons between the three NVC patterns were by a non-
parametric Kruskal-Wallis test. A multiple linear
regression analysis was also performed for all variables
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identified with P ≤ 0.1 univariately. P values < 0.05 were
considered significant.
Results
Study population
The discovery cohort consisted of 60 consecutive SSc
patients (46 women, 77%), with a median (range) age of
53.5 years (28 to 81 years) and median (range) disease
duration of 9 years (1 to 50 years). Thirty-six (60%)
patients had the diffuse cutaneous subset, and 24, the lim-
ited. Their baseline characteristics are shown in Table 1.
The replication cohort consisted on 43 patients with
SSc (33 women, 77%), with a median (range) age of 57
years (34 to 80 years) and median (range) disease dura-
tion of 7 years (1 to 29 years). Fifteen (35%) patients
had the diffuse cutaneous subset, and 28, the limited.
Qualitative capillaroscopic assessment
Fourteen (23%) patients had an early-, 22 (37%), an
active-, and 24 (40%), a late-NVC SSc pattern in the dis-
covery cohort. In the replication cohort, eight (19%)
patients had an early-, 20 (46%) an active-, and 15 (35%)
a late-NVC pattern.
Levels of endothelial factors
To assess the validity of flow cytometry and ELISA mea-
surements, we compared the levels of endothelial mar-
kers observed in SSc patients with the values obtained
in a population of 20 healthy age- and sex-matched con-
trols [15,29]. EPC levels were significantly higher than
those of controls, in agreement with our previous results
[15], and CEC levels were significantly decreased in SSc
patients (see Additional file 2). Serum levels of VEGF,
PlGF, endostatin, endothelin-1, and angiopoietin-2 were
significantly higher in SSc patients; and no difference
was observed with controls for sVCAM, endoglin, and
Tie-2 serum levels (Additional file 2).
Levels of endothelial factors and NVC patterns
In univariate analysis focused on vascular factors,
patients from the discovery cohort and with the late-
NVC pattern exhibited significantly lower EPC levels
than did patients with early and active patterns (median
EPC levels, 31/106 Lin-mononuclear cells in the late-
NVC pattern versus 61 and 82/106 Lin-mononuclear
cells in the early- and active-NVC patterns, respectively;
P < 0.0001) (Table 2 and Figure 1A, B).
In the discovery cohort, higher VEGF serum levels were
observed in the late-NVC pattern (median VEGF serum
levels, 814 pg/ml), as compared with the early- (518 pg/
ml) and active- (493 pg/ml) NVC patterns (P = 0.01)
(Table 2 and Figure 1C, D). This result was confirmed in
the replication cohort (median VEGF levels in the late-
NVC pattern: 708 pg/ml versus 445 pg/ml in patients with
the early- or active-NVC pattern; P = 0.01) (Figure 2A),
and in the combined population of 103 patients (median
VEGF levels in the late-NVC pattern: 770 pg/ml versus
483 pg/ml in patients with the early- or active-NVC pat-
tern; P = 0.003) (Figure 2B).
Endothelin-1 serum levels were significantly higher in
the active pattern (2.5 pg/ml) compared with the early and
late patterns (1.5 and 1.7 pg/ml; P = 0.02) in the discovery
cohort (Table 2). This result was not confirmed in the
replication cohort (median endothelin-1 levels in the
active NVC pattern: 2.9 pg/ml versus 2.1 pg/ml in patients
with the early-NVC pattern and 3.2 pg/ml in patients with
the late-NVC pattern; P = 0.2), or in the combined cohort.
No association was observed between the levels of
other serum markers and NVC patterns in the discovery
cohort (Table 2).
Table 1 Characteristics of the 60 patients with systemic sclerosis included in the discovery cohort
Age (years), median (range) 53.5 (28-81)
Disease duration (years), median (range) 9 (1-50)
Limited/Diffuse cutaneous subset, n (%) 36 (60)/24 (40)
Modified Rodnan skin score > 14, n (%) 19 (32)
History of digital ulcers, n (%) 29 (47)
Pulmonary fibrosis on CT scan, n (%) 28 (47)
Pulmonary arterial hypertension on RHC, n (%) 4 (7)
Positive antinuclear antibodies (> 1/160), n (%) 53 (88)
Positive antitopoisomerase-1 antibodies, n (%) 28 (47)
Positive anticentromere antibodies, n (%) 12 (20)
FVC < 75% predicted, n (%) 13 (22)
DLCO/AV < 75% predicted, n (%) 23 (38)
Treatment with calcium channel blockers, n (%) 60 (100)
Treatment with angiotensin-converting enzyme inhibitors, n (%) 19 (32)
Treatment with endothelin-receptor antagonists and/or PDE5 inhibitors, n (%) 12 (20)
DLCO/AV, diffusing capacity for carbon monoxide/alveolar volume; FVC, forced vital capacity; PDE5, phosphodiesterase type 5; RHC, right heart catheterization.
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Table 2 Nailfold videocapillaroscopy patterns and endothelial marker levels in peripheral blood or serum of patients
with systemic sclerosis included in the discovery cohort
Capillaroscopy pattern P value
Early
Median (range)
Active
Median (range)
Late
Median (range)
EPCs (106 Lin-mononuclear cells) 61 (29-573) 82 (21-300) 31 (5-300) < 0.0001
CECs (106 Lin-mononuclear cells) 81 (10-342) 36 (5-155) 77 (6-472) 0.4
VEGF (pg/ml) 518 (161-1,028) 493 (156-1,146) 814 (189-1,564) 0.01
PlGF (pg/ml) 9.6 (4.6-24.2) 9.9 (0.7-19.6) 10.5 (2.3-26.5) 0.8
sVCAM-1 (ng/ml) 766 (482-1,828) 694 (354-1,405) 767 (459-1,314) 0.4
Tie-2 (ng/ml) 24.4 (12.9-29.4) 21.1 (14.1-27.1) 22.2 (16-39.6) 0.3
Endostatin (ng/ml) 185 (88-477) 139 (54-178) 150 (22-662) 0.3
Endoglin (CD105) (ng/ml) 3.7 (1.9-5.0) 3.9 (2.8-5.6) 3.5 (2.6-5.1) 0.5
Endothelin-1 (pg/ml) 1.5 (1.0-3.6) 2.5 (0.9-7.2) 1.7 (0.4-3.1) 0.02
Angiopoietin-2 (pg/ml) 2,166 (1241-3,312) 2,016 (1,249-4,027) 2202 (1,512-5,148) 0.5
von Willebrand factor antigen (%) 180 (95-266) 169 (69-304) 170 (83-302) 0.9
Figure 1 Levels of circulating endothelial progenitor cells (Lin-7AAD-CD133+CD34+VEGFR2+ cells) (A, B) and VEGF serum levels (C, D)
in the discovery cohort according to the nailfold videocapillaroscopy pattern.
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In multivariable analysis performed with multiple linear
regression, including EPC counts, VEGF serum levels, and
endothelin serum levels, only EPC counts (r = -0.41; P =
0.003) and VEGF serum levels (r = 0.36; P = 0.001) were
independently associated with the late-NVC pattern.
SSc disease characteristics and NVC patterns in the
discovery cohort
The c2 analysis performed revealed several associations
between the late-NVC pattern and SSc-related disease
characteristics (Table 3). Patients with the late-NVC pat-
tern were more likely to have an mRSS > 14 (13 of 24,
54%, versus six of 36, 17%; P = 0.005) and a history of digi-
tal ulcers (16 of 24, 67%, versus 13 of 36, 36%; P = 0.03)
than patients with the early- or the active-NVC pattern. In
addition, the likelihood of positive antitopoisomerase-I
antibodies (16 of 24, 67%, versus 12 of 36, 33%; P = 0.02)
and decreased DLCO/AV < 75% (14 of 24, 58%, versus
nine of 36, 25%; P = 0.02) was significantly higher in
patients with the late-NVC pattern.
In multiple linear regression analysis performed for all
variables identified with P ≤ 0.10 univariately, an mRSS >
14 (r = 0.42; P = 0.0008), history of digital ulcers (r = 0.25;
P = 0.03), and an FVC < 75% (r = 0.29; P = 0.01) were inde-
pendently associated with the late-NVC pattern (Table 3).
Angiogenic factors, SSc disease characteristics, and NVC
patterns
We next tested an alternate multiple linear regression
model including both angiogenic markers independently
associated with the late-NVC pattern (circulating EPCs
and VEGF serum levels) and SSc-related disease charac-
teristics associated univariately with P ≤ 0.10 with the
late-NVC pattern.
In this model, lower EPC counts (r = -0.45; P = 0.005)
and higher VEGF levels (r = 0.37; P = 0.01) remained inde-
pendently associated with the late-NVC pattern, together
with a modified Rodnan skin (mRSS) score > 14 (r = 0.50;
P < 0.0001) and history of digital ulcerations (r = 0.25; P =
0.04) (Table 4).
Discussion
This is the first study to show decreased EPC counts
and increased VEGF serum levels in patients with the
late-NVC pattern.
Reduced EPC numbers in the late-NVC pattern suggest
that deficient vasculogenesis may contribute to the severe
loss of capillaries observed in this pattern. Indeed,
decreased EPC numbers can lead to insufficient endothe-
lial repair and depressed new blood vessels formation that
could be related to the extensive areas of desertification.
Decreased EPC levels in this stage may be consistent with
decreased mobilization from the bone marrow, as sug-
gested in a previous study [30]. In the latter study, the
stromal compartment of SSc bone marrow was defective
in functional EPCs, particularly in patients with late-phase
disease. Decreased EPC levels in the peripheral blood of
patients with the late-NVC pattern could also be related
to an increased EPC homing. Several studies previously
reported that EPCs might be recruited at injured sites
Figure 2 Serum VEGF levels in the replication cohort (A), and combined cohort (B), according to the nailfold videocapillaroscopy pattern.
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during active vascular and severe disease [15,31,32]. These
data support overall insufficient vasculogenesis to counter-
balance vascular damage and might suggest the mobiliza-
tion of EPCs from the bone marrow (for example, with
administration of G-CSF, statins, or erythropoietin) as a
potential target for future therapies in SSc, especially in
patients with the late-NVC pattern [33-35].
The severe capillary loss observed in the late-NVC
pattern might also be related to decreased angiogenesis.
This insufficient angiogenesis might be related to
decreased levels of proangiogenic factors. However, we
detected in two independent and homogeneous cohorts
increased VEGF serum levels in SSc patients with the late-
NVC pattern, compared with patients with the early- or
Table 3 Association between nailfold videocapillaroscopy patterns and disease characteristics of patients with
systemic sclerosis included in the discovery cohort
NVC pattern P value Multiple linear regression
(r)
P value
Early/active
(n = 36)
Late
(n = 24)
Age, median (range) 58 53 0.2
Females, n (%) 27 (75) 19 0.9
Disease duration, median (range) 9.91 7.20 0.2
Diffuse cutaneous subset, n (%) 13 (36) 11 (46) 0.9
Modified Rodnan skin score > 14, n (%) 6 (17) 13 (54) 0.005* 0.42 0.0008
History of digital ulcers, n (%) 13 (36) 16 (67) 0.03* 0.25 0.03
Pulmonary fibrosis, n (%) 15 (42) 13 (54) 0.5
Pulmonary arterial hypertension on RHC, n (%) 2 (6) 2 (8) 0.9
Positive antitopoisomerase antibodies, n (%) 12 (33) 16 (67) 0.02*
Positive anticentromere antibodies, n (%) 9 (25) 3 (13) 0.4
FVC < 75, n (%) 5 (14) 8 (33) 0.1* 0.29 0.01
DLCO/VA < 75%, n (%) 9 (25) 14 (58) 0.02*
Treatment with angiotensin-converting enzyme
inhibitors, n (%)
8 (22) 11 (46) 0.09*
Treatment with endothelin-receptor antagonists and/or
PDE5 inhibitors, n (%)
4 (11) 8 (33) 0.08*
DLCO/AV, diffusing capacity for carbon monoxide/alveolar volume; FVC, forced vital capacity; NVC, nailfold videocapillaroscopy; PDE5, phosphodiesterase type 5;
RHC, right heart catheterization. * Variables included in multiple regression analysis
Table 4 Alternate multiple linear regression model performed in the discovery cohort and including both angiogenic
factors independently associated with the late-NVC pattern and SSc-related disease characteristics associated
univariately with P ≤ 0.10 with the late-NVC pattern
NVC pattern P value Multiple
linear
regression
(r)
P value
Early/Active
(n = 36)
Late
(n = 24)
Modified Rodnan skin score > 14, n (%) 6 (17) 13 (54) 0.005* 0.50 < 0.0001
History of digital ulcers, n (%) 13 (36) 16 (67) 0.03* 0.25 0.04
Positive antitopoisomerase antibodies, n (%) 12 (33) 16 (67) 0.02*
FVC < 75, n (%) 5 (14) 8 (33) 0.1*
DLCO/VA < 75%, n (%) 9 (25) 14 (58) 0.02*
Treatment with angiotensin-converting enzyme inhibitors, n (%) 8 (22) 11 (46) 0.09*
Treatment with endothelin-receptor antagonists and/or PDE5 inhibitors, n (%) 4 (11) 8 (33) 0.08*
EPCs (106 Lin-mononuclear cells), median (range) 64 (21-573) 31 (5-300) < 0.0001* -0.45 0.005
VEGF (pg/ml), median (range) 470 (156-1,146) 814 (189-1,564) 0.01* 0.37 0.01
DLCO/AV, diffusing capacity for carbon monoxide/alveolar volume; FVC, forced vital capacity; NVC, nailfold videocapillaroscopy. * Variables included in multiple
regression analysis
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active-NVC pattern. Thus, VEGF upregulation may appear
as an insufficient compensatory mechanism to stimulate
angiogenesis. In addition, the observation of lower EPC
counts in the late-NVC pattern also supports that vasculo-
genesis is not sufficiently compensated by VEGF upregula-
tion. This result is in accordance with those of other
research groups that found significantly higher VEGF
levels in the late stages of the disease, as compared with
the levels in patients with recent onset [12,31]. Moreover,
an inverse correlation between serum VFGF levels and
capillary density has been reported [32,36]. The same find-
ings have been observed in systemic lupus erythematosus:
significantly higher VEGF serum levels have been detected
in patients with decreased capillary density and neoangio-
genesis (> 75% morphologically changed loops, as tortu-
ous, enlarged, and/or disarranged capillaries) [37]. In
addition, a prolonged overexpression of VEGF may have
deleterious effects on the vascular network, because it may
result in a chaotic vascular morphology with reduced
blood flow in the newly formed vessels. A chronic and
uncontrolled overexpression of VEGF does occur in SSc
and might significantly be implicated in the altered vessel
morphology observed in the late-NVC pattern [38].
We did not find any differential concentration of other
proangiogenic markers (PlGF, angiopoietin-2, and Tie-2)
between the different NVC patterns. One recent pre-
vious study identified a trend for higher angiopoietin-2
levels in patients with the late-NVC pattern with respect
to those with an early/active pattern [17]. This discre-
pancy may be explained by the characteristics of the
study populations (lower proportion of patients with the
diffuse cutaneous subset and higher disease duration in
our study) and by the measurement of angiopoietin-2 in
the serum in our study, versus plasma in the other
study. The insufficient angiogenesis observed in the late-
NVC pattern might also be related to increased levels of
angiostatic factors, which have been reported to be pre-
dominant in the late stages of SSc. However, we did not
observe increased levels of endostatin and endoglin, two
major inhibitors of angiogenesis. Further evaluation of
other angiostatic markers should be assessed to confirm
these findings.
We also determined whether SSc-disease characteristics
might be associated with NVC patterns. No association
was noted between the late-NVC pattern and disease
duration, which supports that patients with early disease
may experience severe vascular loss not sufficiently com-
pensated by new-vessel formation. We found that the late-
NVC pattern was associated in univariate analysis with
more-severe vascular manifestations (history of digital
ulcers) or with the presence of markers of a more-diffuse
SSc subset (mRSS > 14 and antitopoisomerase-I antibo-
dies). Multivariate analysis confirmed the independent
association between the late-NVC pattern and the follow-
ing characteristics: history of digital ulcers, mRSS > 14,
and an FVC < 75% of predicted; which support a more-
severe and fibrotic propensity of the late-NVC pattern.
These results are consistent with previously published
data, which showed that patients with the late-NVC pat-
tern have an increased risk to experience digital ulcers,
more-severe skin thickening, and decreased FVC and
DLCO, compared with patients with early and active pat-
terns [39]. In addition, an mRSS > 14 remained indepen-
dently associated with the late-NVC pattern after the
inclusion of the endothelial markers in the statistical
model. These results support the more severe and fibrotic
propensity of the late-NVC pattern.
Our study has several limitations that deserve consid-
eration. Our study is limited by its observational design,
and any pathogenic link emerging from this type of
study should be taken very cautiously. Our sample size
was too limited to assess adequately disease phenotype
associations in specific subsets of patients, especially
those with confirmed pulmonary arterial hypertension,
or those with active digital ulcers. In addition, our NVC
assessment was only qualitative, based on pattern recog-
nition. Next to associations between endothelial factors
and qualitative NVC assessment, efforts should be
further made to find associations with quantitative
assessment, based on counting of hallmark parameters
of the SSc pattern. Now quantitative assessment has to
find a definite place in research settings and also in
daily practice. Thus, further evaluation of endothelial
markers with some recently proposed quantitative
index/scores might be performed to confirm our find-
ings obtained with pattern recognition [40-42].
Conclusions
Our data revealed decreased EPC counts and VEGF
upregulation in patients with the late-NVC pattern.
Further studies are now needed to determine the
respective role of EPCs and VEGF in endothelial injury
and endothelial repair in SSc.
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